STOCK TITAN

ProKidney - PROK STOCK NEWS

Welcome to our dedicated page for ProKidney news (Ticker: PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney stock.

ProKidney Corp (NASDAQ: PROK) is a clinical-stage biotechnology leader developing autologous cellular therapies for chronic kidney disease. This page provides centralized access to official company announcements, clinical trial updates, and strategic developments.

Investors and researchers will find timely updates on PROK's REACT therapy progress, including Phase 3 trial results, regulatory interactions with the FDA/EMA, and manufacturing advancements. Our news collection features earnings reports, partnership announcements, and scientific presentations - all essential for understanding the company's position in regenerative medicine.

The repository includes:
- Clinical trial milestones and data readouts
- Regulatory submissions and designations (including RMAT status)
- Financial performance updates
- Strategic collaborations in nephrology research
- Peer-reviewed study publications

Bookmark this page for verified updates about ProKidney's innovative approach to preserving kidney function through cellular therapy. Check regularly for new developments in this rapidly evolving therapeutic area.

Rhea-AI Summary

ProKidney, a late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced the pricing of its upsized $130 million public offering of Class A ordinary shares. The offering consists of 53,719,009 shares at $2.42 per share, with an option for underwriters to purchase an additional 15% within 30 days. The public and registered direct offerings are expected to close around June 13, 2024, subject to customary conditions.

Proceeds will fund clinical trial costs, research and development, pre-commercial and commercial activities, and general corporate purposes. Jefferies, J.P. Morgan, and Guggenheim Securities are managing the underwritten public offering, with PJT Partners serving as co-manager and financial advisor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.55%
Tags
-
Rhea-AI Summary

ProKidney (NASDAQ: PROK) has announced a proposed $125 million public offering of Class A ordinary shares, including an underwritten public offering and a concurrent registered direct offering.

The company is offering all the shares and may grant underwriters a 30-day option to purchase an additional 15% of the shares. Certain investment entities, including those affiliated with ProKidney's chairman, are interested in purchasing shares but have no binding commitments.

Proceeds will be used for clinical trial costs, R&D expenses, and commercial activities. Jefferies, J.P. Morgan, and Guggenheim Securities are joint book-running managers, while PJT Partners acts as co-manager and financial advisor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.87%
Tags
-
Rhea-AI Summary

ProKidney has announced positive interim results for its Phase 2 REGEN-007 trial focusing on chronic kidney disease (CKD) caused by diabetes. The trial showed stabilization of kidney function over 18 months, with a safety profile consistent with prior studies. The company has resumed manufacturing and restarted its Phase 3 trials PROACT 1 and PROACT 2. Operational updates include resumed patient screening and site activations in Spain. Management will discuss these developments in a live webcast today at 8:00 a.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
Rhea-AI Summary

ProKidney, a late clinical-stage cellular therapeutics company specializing in chronic kidney disease (CKD), announced its participation in the Jefferies Global Healthcare Conference. The event is scheduled from June 4 to June 6, 2024, in New York, NY.

Senior management will host one-on-one meetings with investors during the conference. To arrange meetings, investors are advised to contact their Jefferies representative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.74%
Tags
conferences
-
Rhea-AI Summary

ProKidney Corp. (Nasdaq: PROK) is hosting a virtual KOL event on May 28, 2024, to discuss the treatment landscape for chronic kidney disease (CKD) caused by diabetes. The event will feature experts Steven G. Coca and Arnold L. Silva, who will address the unmet medical needs and the importance of preserving kidney function in patients with moderate to severe CKD. The event will also cover final data from the RMCL-002 Phase 2 trial of ProKidney's lead product candidate, rilparencel (REACT®), which will be presented at the European Renal Association (ERA) Congress on May 25, 2024. A live Q&A session will follow the presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
conferences clinical trial
-
Rhea-AI Summary

ProKidney Corp. reported business updates and financial results for Q1 2024, highlighting upcoming clinical trial data presentations, leadership team enhancements, and financial performance. The Company ended the quarter with $329 million in cash and securities to support operations into Q4 2025. Notably, ProKidney aims to advance its therapeutic options for CKD patients with upcoming Phase 3 trials and a strong focus on preserving kidney function in high-risk populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.66%
Tags
Rhea-AI Summary
ProKidney Corp. (PROK) announces strategic appointments of Dr. Ulrich Ernst as Executive Vice President of Technical Operations and Mr. Lucio Tozzi as Senior Vice President of Global Clinical Operations. Dr. Ernst brings 30 years of experience in process development and manufacturing of cell therapies, while Mr. Tozzi has extensive experience in clinical trial execution. Their expertise aims to enhance ProKidney's leadership team for the completion of Phase 3 program and future commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
Rhea-AI Summary
ProKidney Corp. (PROK) releases financial results for 2023, showing significant revenue growth and positive clinical developments in CKD treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
-
Rhea-AI Summary
ProKidney Corp. to Participate in Jefferies Biotech on the Bay Summit, Focusing on Cellular Therapeutics for Chronic Kidney Disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
Rhea-AI Summary
ProKidney Corp. (Nasdaq: PROK) appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer, leveraging his extensive experience in new business development and strategic partnerships from his role as former CEO of Africa Healthcare Network. Mr. Pereira-Kamath's global responsibility for commercial strategy and investor relations aims to drive the company's growth and potential commercialization of their lead program, REACT®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.16%
Tags
management
ProKidney

Nasdaq:PROK

PROK Rankings

PROK Stock Data

103.10M
90.89M
27.17%
44.14%
9.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WINSTON-SALEM